A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Eleclazine (Primary)
  • Indications Ventricular arrhythmias
  • Focus Therapeutic Use
  • Acronyms TEMPO
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 03 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 28 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Oct 2016.
    • 07 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top